Completed PHASE1 INTERVENTIONAL 2-arm NCT01290172

Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.

A Single-center, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.

Sponsor: University Hospital, Ghent

Conditions Liver Transplant With Clinically Significant Portal Hypertension

Interventions Administration of Somatostatin Administration of placebo

Updated 5 times since 2017 Last updated: Nov 27, 2014 Started: Dec 31, 2010 Primary completion: Dec 31, 2013 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Liver Transplant With Clinically Significant Portal Hypertension, this trial is completed. The trial is conducted by University Hospital, Ghent and has accumulated 5 data snapshots since 2010. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital, Ghent

Data source: University Hospital, Ghent

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ghent, Belgium